793 related articles for article (PubMed ID: 25593131)
1. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
2. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
4. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
6. An α
Kuo YJ; Chen YR; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2017 Nov; 15(11):2230-2244. PubMed ID: 28815933
[TBL] [Abstract][Full Text] [Related]
7. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
[TBL] [Abstract][Full Text] [Related]
8. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.
Münzer P; Borst O; Walker B; Schmid E; Feijge MA; Cosemans JM; Chatterjee M; Schmidt EM; Schmidt S; Towhid ST; Leibrock C; Elvers M; Schaller M; Seizer P; Ferlinz K; May AE; Gulbins E; Heemskerk JW; Gawaz M; Lang F
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):61-71. PubMed ID: 24233488
[TBL] [Abstract][Full Text] [Related]
9. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
Vaduganathan M; Bhatt DL
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
[No Abstract] [Full Text] [Related]
11. RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.
Jones ML; Harper MT; Aitken EW; Williams CM; Poole AW
J Thromb Haemost; 2010 Mar; 8(3):567-76. PubMed ID: 20002543
[TBL] [Abstract][Full Text] [Related]
12. A novel antibody targeting the ligand binding domain of the thromboxane A₂ receptor exhibits antithrombotic properties in vivo.
Murad JP; Espinosa EV; Ting HJ; McClure D; Khasawneh FT
Biochem Biophys Res Commun; 2012 May; 421(3):456-61. PubMed ID: 22503974
[TBL] [Abstract][Full Text] [Related]
13. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice.
Hechler B; Nonne C; Roh EJ; Cattaneo M; Cazenave JP; Lanza F; Jacobson KA; Gachet C
J Pharmacol Exp Ther; 2006 Feb; 316(2):556-63. PubMed ID: 16236815
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
15. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
[TBL] [Abstract][Full Text] [Related]
16. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
17. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
18. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.
Rand ML; Wang H; Pluthero FG; Stafford AR; Ni R; Vaezzadeh N; Allison AC; Kahr WH; Weitz JI; Gross PL
J Thromb Haemost; 2012 Jun; 10(6):1109-19. PubMed ID: 22463102
[TBL] [Abstract][Full Text] [Related]
19. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
